- Home
- KZIA vs MBIO Comparison
KZIA vs MBIO Comparison
Compare KZIA & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | MBIO |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.5M | 4.7M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | KZIA | MBIO |
|---|---|---|
| Price | $9.88 | $1.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 99.4K |
| Earning Date | 12-26-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,199,108.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $0.89 |
| 52 Week High | $18.20 | $21.95 |
Technical Indicators
Market Signals| Indicator | KZIA | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 35.91 |
| Support Level | $8.91 | $1.06 |
| Resistance Level | $12.20 | $1.31 |
| Average True Range (ATR) | 2.42 | 0.09 |
| MACD | -0.51 | -0.01 |
| Stochastic Oscillator | 23.97 | 2.70 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.